ROCKVILLE, Md., Feb. 18 /PRNewswire-USNewswire/ --- Biotech pioneer William J. Rutter, PhD, will deliver a keynote speech at the 2008 RAPS Horizons Conference & Exhibition in San Francisco next month, the Regulatory Affairs Professionals Society (RAPS) has announced.
Rutter, Chairman and CEO of Synergenics LLC and co-founder of biotech industry leader Chiron, will stimulate fresh and relevant perspectives on the regulatory implications of advances in biological and medical science that are driving new products and individually-oriented treatment strategies.
Among the issues Rutter will address:
-- Individualized cancer drug therapy
-- Cancer vaccines
-- Genetic-based therapy
-- Immunological control of disease via administered antibodies or vaccines
-- Stem cell therapy
"Dr. Rutter's unique experience with the rapidly shifting nature of science and healthcare products will provide us with crucial insight into evolving treatment regimens/protocols and regulatory strategies," said RAPS Executive Director Sherry L. Keramidas, PhD, CAE.
Under Rutter's leadership, Chiron placed a major emphasis on detection, prevention and treatment of infectious diseases. With Merck, Chiron developed a Hepatitis B vaccine, based on the Hepatitis B pseudoparticles from yeast. Rutter's commitment to funding research on important diseases led to two of Chiron's most enduring achievements: the cloning and first sequencing of the HIV genome in 1984, and the discovery, sequencing and cloning of the hepatitis C virus in 1987.
Keramidas emphasized the commonalities of innovation across various healthcare product lines, including devices, drugs and biotechnology, and the need to utilize the most recent science to discover new treatments and to bring these treatments to consumers safely and more efficiently.
Additionally, Keramidas said that regulatory professionals are increasingly working in more than one of these product areas, often focusing on a wide array of products launched in a number of regions worldwide.
"Our members are working across product lines and across the globe. Dr. Rutter's breakthroughs and scientific leadership are instructional for all regulatory professionals," said Keramidas.
The 2008 RAPS Horizons Conference & Exhibition, scheduled 26-28 March at the Fairmont San Francisco, is expected to draw hundreds of scientists, regulatory leaders and professionals from the biotechnology, pharmaceutical and medical device industries, government, academia, research and clinical organizations.
For more information or to register for Horizons, visit the RAPS website, http://www.raps.org/horizons.
The Regulatory Affairs Professionals Society (RAPS) guides and supports individuals--from industry, government, academia, research and clinical organizations--to bring life-saving and life-enhancing products to the global marketplace quickly and safely.
Founded in 1976 and operating outside the political arena, RAPS provides a neutral forum on emerging science and global regulatory challenges, offering personal and professional resources to help regulatory professionals continuously improve and work smarter, faster and in compliance with regulatory models.
RAPS established the regulatory profession worldwide and brings knowledge and progress to it. By identifying s, developing professional certification, and providing educational and networking opportunities, RAPS supports professionals throughout the healthcare product lifecycle. http://www.raps.org
|SOURCE Regulatory Affairs Professionals Society (RAPS)|
Copyright©2008 PR Newswire.
All rights reserved